Loading...
Market
Story
Pfizer's Talzenna-Xtandi Combo Significantly Prolongs Survival in Final Phase 3 Prostate Cancer Study
Oct 10, 2024, 10:55 AM
Pfizer announced that the combination of Talzenna (talazoparib) and Xtandi (enzalutamide) significantly extended overall survival in men with metastatic castration-resistant prostate cancer (mCRPC), according to the final prespecified overall survival analysis of the phase 3 TALAPRO-2 trial. The study demonstrated that the drug combination significantly prolonged patients' lives compared to enzalutamide alone, offering a promising new treatment option for this aggressive form of prostate cancer.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Bristol-Myers Squibb • 25%
Merck & Co. • 25%
Pfizer • 25%
Other • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Optune Lua with PD-1/PD-L1 inhibitors • 25%
Sunvozertinib • 25%
Durvalumab with chemotherapy • 25%
Other • 25%
Leading • 25%
Second • 25%
Third • 25%
Lower • 25%
Less than 40% • 25%
40% to 50% • 25%
51% to 60% • 25%
More than 60% • 25%